• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于交变电场技术的全自动快速免疫组织化学法评估乳腺癌雌激素受体分级

Evaluation of Grading Estrogen Receptors in Breast Cancer Using Fully Automated Rapid Immunohistochemistry Based on Alternating-Current Electric Field Technology.

作者信息

Kudo Chiaki, Terata Kaori, Nanjo Hiroshi, Nomura Kyoko, Hiroshima Yuko, Takahashi Eriko, Yamaguchi Ayuko, Konno Hikari, Onji Masaaki, Wakamatsu Yuki, Kimura Yoshihiko, Takashima Shinogu, Wakita Akiyuki, Sato Yusuke, Minamiya Yoshihiro, Imai Kazuhiro

机构信息

Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita 010-8543, Japan.

Department of Breast and Endocrine Surgery, Akita University Hospital, Akita 010-8543, Japan.

出版信息

Cancers (Basel). 2025 Jan 23;17(3):363. doi: 10.3390/cancers17030363.

DOI:10.3390/cancers17030363
PMID:39941732
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11816054/
Abstract

BACKGROUND

Immunohistochemistry (IHC) is crucial for determining cancer treatments. We previously developed a rapid IHC method and have now developed a fully automated rapid IHC stainer (R-Auto). This study aimed to evaluate the clinical reliability of the R-Auto protocol for staining estrogen receptors (ERs) in breast cancer specimens and evaluate the staining performance.

METHODS

Between January 2015 and June 2020, 188 surgical specimens collected from breast cancer patients treated at our hospital were evaluated via ER staining using R-Auto, conventional manual IHC, and a commercial autostainer. The specimens were scored using Allred scores, after which the staining results were compared between R-Auto and conventional IHC or the commercial autostainer. Weighted kappa coefficients and AC statistics were used to assess the agreement between the methods.

RESULTS

The AC statistic for comparison between R-Auto and conventional IHC was 0.9490 (0.9139-0.9841), with a 95.7% agreement rate, and that for comparison between R-Auto and the commercial autostainer was 0.9095 (0.8620-0.9570), with a 92.6% agreement. There was, thus, substantial agreement between R-Auto and both conventional IHC and the commercial autostainer. However, R-Auto shortened the time required for IHC from 209 min with conventional IHC to 121 min.

CONCLUSIONS

R-Auto enables a good staining performance in a shorter time with less effort.

摘要

背景

免疫组织化学(IHC)对于确定癌症治疗方案至关重要。我们之前开发了一种快速免疫组织化学方法,现在又开发了一种全自动快速免疫组织化学染色仪(R-Auto)。本研究旨在评估R-Auto方案对乳腺癌标本中雌激素受体(ER)进行染色的临床可靠性,并评估其染色性能。

方法

2015年1月至2020年6月期间,对我院收治的乳腺癌患者的188份手术标本进行评估,分别采用R-Auto、传统手动免疫组织化学方法和商用自动染色仪进行ER染色。使用艾尔雷德评分对标本进行评分,然后比较R-Auto与传统免疫组织化学方法或商用自动染色仪的染色结果。采用加权kappa系数和AC统计量来评估方法之间的一致性。

结果

R-Auto与传统免疫组织化学方法比较的AC统计量为0.9490(0.9139-0.9841),一致率为95.7%;R-Auto与商用自动染色仪比较的AC统计量为0.9095(0.8620-0.9570),一致率为92.6%。因此,R-Auto与传统免疫组织化学方法和商用自动染色仪之间均有高度一致性。然而,R-Auto将免疫组织化学所需时间从传统免疫组织化学方法的209分钟缩短至121分钟。

结论

R-Auto能够在更短时间内以更少的工作量实现良好的染色性能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/265f/11816054/d9561616ed24/cancers-17-00363-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/265f/11816054/5e7217037e85/cancers-17-00363-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/265f/11816054/af84acac30c3/cancers-17-00363-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/265f/11816054/d9561616ed24/cancers-17-00363-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/265f/11816054/5e7217037e85/cancers-17-00363-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/265f/11816054/af84acac30c3/cancers-17-00363-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/265f/11816054/d9561616ed24/cancers-17-00363-g003.jpg

相似文献

1
Evaluation of Grading Estrogen Receptors in Breast Cancer Using Fully Automated Rapid Immunohistochemistry Based on Alternating-Current Electric Field Technology.基于交变电场技术的全自动快速免疫组织化学法评估乳腺癌雌激素受体分级
Cancers (Basel). 2025 Jan 23;17(3):363. doi: 10.3390/cancers17030363.
2
Validation of CanAssist Breast immunohistochemistry biomarkers on an automated platform and its applicability in tissue microarray.CanAssist乳腺免疫组化生物标志物在自动化平台上的验证及其在组织芯片中的应用
Int J Clin Exp Pathol. 2021 Oct 15;14(10):1013-1021. eCollection 2021.
3
Estrogen receptor antibody incubation time and extent of immunoreactivity in invasive carcinoma of the breast: the importance of optimizing antibody avidity.雌激素受体抗体孵育时间及乳腺浸润性癌中免疫反应性程度:优化抗体亲和力的重要性
Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):203-7. doi: 10.1097/01.pai.0000209861.90086.58.
4
Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies.在雌激素受体阴性和低表达的乳腺癌患者中准确进行雌激素受体定量检测:两项临床研究数据的亚组分析。
Adv Ther. 2019 Apr;36(4):828-841. doi: 10.1007/s12325-019-0896-0. Epub 2019 Mar 11.
5
Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.在常规医院环境中使用两种经过验证的 PD-L1 IHC 22C3 pharmDx 方法检测非小细胞肺癌中的 PD-L1 表达的比较。
Appl Immunohistochem Mol Morphol. 2021 Jan;29(1):49-55. doi: 10.1097/PAI.0000000000000827.
6
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.绝经后激素受体阳性早期乳腺癌患者 ESR1、PGR、ERBB2 和 MKi67 mRNA 表达:ABCGS 试验 6 的结果。
ESMO Open. 2021 Aug;6(4):100228. doi: 10.1016/j.esmoop.2021.100228. Epub 2021 Aug 7.
7
Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study.基于微流控的乳腺癌诊断免疫组织化学:一项临床对比研究。
Virchows Arch. 2019 Sep;475(3):313-323. doi: 10.1007/s00428-019-02616-7. Epub 2019 Jul 2.
8
Rapid intraoperative Ki-67 immunohistochemistry for lung cancer using non-contact alternating current electric field mixing.利用非接触交流电场混合技术快速进行肺癌术中 Ki-67 免疫组化检测。
Lung Cancer. 2022 Nov;173:75-82. doi: 10.1016/j.lungcan.2022.09.007. Epub 2022 Sep 17.
9
Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.免疫组织化学与聚合酶链反应在评估乳腺癌雌激素受体(ER)、孕激素受体(PR)和Ki-67以及预测病理完全缓解方面的比较
BMC Cancer. 2017 Feb 13;17(1):124. doi: 10.1186/s12885-017-3111-1.
10
Estrogen Receptor-α Quantification in Breast Cancer: Concordance Between Immunohistochemical Assays and mRNA-In Situ Hybridization for ESR1 Gene.乳腺癌中雌激素受体-α的定量检测:免疫组织化学检测与 ESR1 基因 mRNA 原位杂交的一致性。
Appl Immunohistochem Mol Morphol. 2020 May/Jun;28(5):347-353. doi: 10.1097/PAI.0000000000000760.

本文引用的文献

1
Multiplex Intraoperative Rapid Immunohistochemistry with Noncontact Antibody Mixing for Distinguishing the Histologic Phenotype of Lung Cancer.用于区分肺癌组织学表型的非接触抗体混合多重术中快速免疫组织化学
Pathobiology. 2024;91(6):383-392. doi: 10.1159/000539640. Epub 2024 Jun 24.
2
Ribociclib plus Endocrine Therapy in Early Breast Cancer.来曲唑联合内分泌治疗早期乳腺癌。
N Engl J Med. 2024 Mar 21;390(12):1080-1091. doi: 10.1056/NEJMoa2305488.
3
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.曲妥珠单抗-德鲁替康与曲妥珠单抗-美坦新用于乳腺癌。
N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.
4
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.21 基因检测在淋巴结阳性乳腺癌中预测化疗获益。
N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056/NEJMoa2108873. Epub 2021 Dec 1.
5
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).阿贝西利联合内分泌治疗用于 HR+、HER2-、淋巴结阳性、高危、早期乳腺癌的辅助治疗(monarchE)。
J Clin Oncol. 2020 Dec 1;38(34):3987-3998. doi: 10.1200/JCO.20.02514. Epub 2020 Sep 20.
6
Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer.新辅助化疗延迟对乳腺癌患者总生存的影响。
Oncologist. 2020 Sep;25(9):749-757. doi: 10.1634/theoncologist.2019-0744. Epub 2020 Jul 7.
7
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.全球、区域和国家癌症发病率、死亡率、生命损失年数、失能生存年数以及 29 种癌症组别的伤残调整生命年数:1990 至 2017 年全球疾病负担研究的系统分析。
JAMA Oncol. 2019 Dec 1;5(12):1749-1768. doi: 10.1001/jamaoncol.2019.2996.
8
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.帕博西尼联合来曲唑作为雌激素受体阳性/人表皮生长因子受体 2 阴性晚期乳腺癌的一线治疗,随访时间延长。
Breast Cancer Res Treat. 2019 Apr;174(3):719-729. doi: 10.1007/s10549-018-05125-4. Epub 2019 Jan 10.
9
Reagent-saving immunohistochemistry for HER2 using non-contact alternating current electric field mixing.使用非接触式交流电混合场进行节约试剂的 HER2 免疫组化。
J Clin Pathol. 2019 Jan;72(1):25-30. doi: 10.1136/jclinpath-2018-205325. Epub 2018 Sep 18.
10
Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility.子宫内膜癌中P53免疫组化的解读:提高可重复性
Int J Gynecol Pathol. 2019 Jan;38 Suppl 1(Iss 1 Suppl 1):S123-S131. doi: 10.1097/PGP.0000000000000488.